Marker Therapeutics, Inc. (Nasdaq: MRKR) shared positive pre-clinical data regarding their T cell product candidate, MT-601, which targets multiple tumor-associated antigens (multiTAA) in lymphoma cells, including those resistant to CD19 CAR T cell therapy. 

The data demonstrated the anti-tumor activity of MT-601 against CD19 CAR T refractory lymphoma cells in vitro, indicating its potential as a therapeutic option.

In pre-market, $MRKR was trading at $1.91, experiencing a significant increase of $0.59 (+44.69%).

On another note, Trevena, Inc. (Nasdaq: TRVN) disclosed that it received a $3 million milestone payment from its partner, Jiangsu Nhwa Pharmaceutical Co. Ltd. (Nhwa), following the approval of OLINVYK in China. Under the exclusive license agreement, Nhwa has the responsibility of developing, manufacturing, and commercializing OLINVYK in China. 

Additionally, Trevena reaffirmed the anticipated receipt of $15 million in non-dilutive financing from R-Bridge upon the first commercial sale of OLINVYK in China, which Nhwa believes will take place in the third quarter of 2023.

$TRVN was trading at $1.37 in pre-market, showing a gain of $0.21 (+18.10%) following the announcement.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)